Top-line results from another two tirzepatide (Mounjaro) weight-loss pivotal trials in adults without diabetes pad the agent s sizeable evidence base and presage likely FDA approval later in 2023.
Doctors and researchers have been trying to end the obesity epidemic for decades and have failed. Can a new set of effective drugs finally succeed? Second in a 3-part series on the obesity crisis.
Tirzepatide s agonist effect on GIP receptors of isolated pancreatic islet cells appears responsible for a good portion of the drug s effects beyond its GLP-1 receptor agonism.
Over 60% of participants achieved the weight-reduction target of 20% or higher and had improved body composition in a phase 3 trial of tirzepatide in overweight/obesity.
A combination of a swallowable Allurion gastric balloon and liraglutide delivers higher weight loss (around 19% after mean 4 months) than use of separate treatments.